COVER; COPYRIGHT; Contents; Abbreviations; Acknowledgements; Foreword; Executive summary; Introduction; Case definitions; Standard treatment regimens; Monitoring during treatment; Co-management of HIV and active TB disease; Supervision and patient support; Treatment of drug-resistant tuberculosis; Treatment of extrapulmonary TB and of TB in special situations; Annexes; Essential first-line antituberculosis drugs; Summary of evidence and considerations underlying the recommendations; TB treatment outcomes; Suggestions for future research
Summary
The World Health Organization's Stop TB Department has prepared this fourth edition of Treatment of Tuberculosis: Guidelines, adhering fully to the new WHO process for evidence-based guidelines. Several important recommendations are being promoted in this new edition. First, the recommendation to discontinue the regimen based on just 2 months of rifampicin (2HRZE/6HE) and change to the regimen based on a full 6 months of rifampicin (2HRZE/4HR) will reduce the number of relapses and failures. This will alleviate patient suffering resulting from a second episode of tuberculosis (TB) and conserve
